ArticleAdvanced healthcare materials2023
Enhancing Pt(IV) Complexes' Anticancer Activity upon Encapsulation in Stimuli-Responsive Nanocages.
Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Fe(III) complexes with prolonged luminescence lifetimes via excited-state equilibration promoted by reversible intercomponent electron transfer.Nature communications · 2026Article
- Melanoma extracellular vesicles membrane coated nanoparticles as targeted delivery carriers for tumor and lungs.Materials today. Bio · 2025Article
- Two Different Responsive Organosilica Nanocarriers to Combine Chemo- and Immunotherapy against Cancer.ACS omega · 2024Article
- Enhancing ovarian cancer treatment with maleimide-modified Pt(IV) prodrug nanoparticles.Materials today. Bio · 2024Article
- Nanocarrier-mediated cancer therapy with cisplatin:Heliyon · 2024Article
- Supramolecular Nucleic Acid-Based Organosilica Nanoparticles Responsive to Physical and Biological Inputs.Journal of the American Chemical Society · 2023Article
- Enhancing Pt(IV) Complexes' Anticancer Activity upon Encapsulation in Stimuli-Responsive Nanocages.Advanced healthcare materials · 2023Article
- The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-based chemotherapy is the first-line treatment for different cancer types, and in particular, for malignant pleural mesothelioma patients (a tumor histotype with urgent medical needs). Herein, a strategy is presented to stabilize, transport, and intracellularly release a platinum
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.